Open AccessCardiovascular manifestation and treatment in COVID-19
Author(s) -
Yen Bo Su,
Ming Kuo,
Ting Lin,
ChianShiu Chien,
Yi Yang,
Shih Jie Chou,
Hsin Bang Leu
Publication year - 2020
Publication title -
journal of the chinese medical association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.535
H-Index - 42
eISSN - 1728-7731
pISSN - 1726-4901
DOI - 10.1097/jcma.0000000000000352
Subject(s) - medicine , myocarditis , disease , intensive care medicine , myocardial infarction , covid-19 , pneumonia , heart failure , diabetes mellitus , pericarditis , pandemic , cardiomyopathy , cardiology , infectious disease (medical specialty) , endocrinology
The novel coronavirus disease 2019 (COVID-19), with first presentation of atypical pneumonia, has spread rapidly from Wuhan, China, on December 12, 2019 to over 200 countries, caused 2 310 572 infected individuals and 158 691 mortalities, updated on April 19, 2020. Many studies have published timely to help global healthcare workers to understand and control the disease. Vulnerable patients with risk factors such as elderly, cardiovascular diseases (eg, hypertension, coronary disease, or cardiomyopathy), diabetes, and chronic kidney disease have worse outcomes after COVID-19 infection. COVID-19 could directly cause cardiovascular injuries such as pericarditis, myocarditis, myocardial infarction, heart failure, arrhythmias, or thromboembolic events, which urge cardiologists to be involved in the frontline to practice. Here, we provide a review of COVID-19 on cardiovascular system to assist clinical cardiologists to better understand the disease and being capable of providing comprehensive medical support.